Tags

Type your tag names separated by a space and hit enter

Stability indicating reversed-phase high-performance liquid chromatographic and thin layer densitometric methods for the determination of ziprasidone in bulk powder and in pharmaceutical formulations.
Biomed Chromatogr. 2004 Apr; 18(3):143-9.BC

Abstract

Two sensitive and reproducible methods were developed and validated for the determination of ziprasidone (ZIP) in the presence of its degradation products in pure form and in pharmaceutical formulations. The fi rst method was based on reversed-phase high-performance liquid chromatography (HPLC), on a Lichrosorb RP C(18) column using water:acetonitrile:phosphoric acid (76:24:0.5 v/v/v) as the mobile phase at a fl ow rate of 1.5 mL min(-1) at ambient temperature. Quantification was achieved with UV detection at 229 nm over a concentration range of 10-500 micro g mL(-1) with mean percentage recovery of 99.71 +/- 0.55. The method retained its accuracy in presence of up to 90% of ZIP degradation products. The second method was based on TLC separation of ZIP from its degradation products followed by densitometric measurement of the intact drug spot at 247 nm. The separation was carried out on aluminium sheet of silica gel 60 F(254) using choloroform:methanol:glacial acetic acid (75:5:4.5 v/v/v) as the mobile phase, over a concentration range of 1-10 micro g per spot and mean percentage recovery of 99.26 +/- 0.39. Both methods were applied successfully to laboratory prepared mixtures and pharmaceutical capsules.

Authors+Show Affiliations

National Organization for Drug Control & Research, Cairo, Egypt.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15103698

Citation

El-Sherif, Zeinab A., et al. "Stability Indicating Reversed-phase High-performance Liquid Chromatographic and Thin Layer Densitometric Methods for the Determination of Ziprasidone in Bulk Powder and in Pharmaceutical Formulations." Biomedical Chromatography : BMC, vol. 18, no. 3, 2004, pp. 143-9.
El-Sherif ZA, El-Zeany B, El-Houssini OM, et al. Stability indicating reversed-phase high-performance liquid chromatographic and thin layer densitometric methods for the determination of ziprasidone in bulk powder and in pharmaceutical formulations. Biomed Chromatogr. 2004;18(3):143-9.
El-Sherif, Z. A., El-Zeany, B., El-Houssini, O. M., Rashed, M. S., & Aboul-Enein, H. Y. (2004). Stability indicating reversed-phase high-performance liquid chromatographic and thin layer densitometric methods for the determination of ziprasidone in bulk powder and in pharmaceutical formulations. Biomedical Chromatography : BMC, 18(3), 143-9.
El-Sherif ZA, et al. Stability Indicating Reversed-phase High-performance Liquid Chromatographic and Thin Layer Densitometric Methods for the Determination of Ziprasidone in Bulk Powder and in Pharmaceutical Formulations. Biomed Chromatogr. 2004;18(3):143-9. PubMed PMID: 15103698.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Stability indicating reversed-phase high-performance liquid chromatographic and thin layer densitometric methods for the determination of ziprasidone in bulk powder and in pharmaceutical formulations. AU - El-Sherif,Zeinab A, AU - El-Zeany,Badr, AU - El-Houssini,Ola M, AU - Rashed,Mohamed S, AU - Aboul-Enein,Hassan Y, PY - 2004/4/23/pubmed PY - 2004/12/22/medline PY - 2004/4/23/entrez SP - 143 EP - 9 JF - Biomedical chromatography : BMC JO - Biomed Chromatogr VL - 18 IS - 3 N2 - Two sensitive and reproducible methods were developed and validated for the determination of ziprasidone (ZIP) in the presence of its degradation products in pure form and in pharmaceutical formulations. The fi rst method was based on reversed-phase high-performance liquid chromatography (HPLC), on a Lichrosorb RP C(18) column using water:acetonitrile:phosphoric acid (76:24:0.5 v/v/v) as the mobile phase at a fl ow rate of 1.5 mL min(-1) at ambient temperature. Quantification was achieved with UV detection at 229 nm over a concentration range of 10-500 micro g mL(-1) with mean percentage recovery of 99.71 +/- 0.55. The method retained its accuracy in presence of up to 90% of ZIP degradation products. The second method was based on TLC separation of ZIP from its degradation products followed by densitometric measurement of the intact drug spot at 247 nm. The separation was carried out on aluminium sheet of silica gel 60 F(254) using choloroform:methanol:glacial acetic acid (75:5:4.5 v/v/v) as the mobile phase, over a concentration range of 1-10 micro g per spot and mean percentage recovery of 99.26 +/- 0.39. Both methods were applied successfully to laboratory prepared mixtures and pharmaceutical capsules. SN - 0269-3879 UR - https://www.unboundmedicine.com/medline/citation/15103698/Stability_indicating_reversed_phase_high_performance_liquid_chromatographic_and_thin_layer_densitometric_methods_for_the_determination_of_ziprasidone_in_bulk_powder_and_in_pharmaceutical_formulations_ DB - PRIME DP - Unbound Medicine ER -